Contract 75A50322F80029
Sagent Pharmaceuticals, Inc · Department Of Health And Human Services · August 22, 2024
Sagent Pharmaceuticals, Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on August 22, 2024 for $47.75 million (current value) of work in pharmaceutical preparation manufacturing. Performance is in Schaumburg, IL. This is a task or delivery order issued under parent IDIQ V797D40094. It uses firm fixed-price contract pricing. If all options are exercised, the contract could reach $47.75 million.
Contract details
- PIID
- 75A50322F80029
- Parent IDIQ
- V797D40094
- Award type
- Delivery Order
- Pricing
- Firm Fixed Price
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Schaumburg, IL
- First action
- August 22, 2024
Description
CIPROFLOXACIN 5% DEXTROSE, INJECTION, 400MG/200ML, (2MG/ML) IS A MEDICAL COUNTERMEASURE (MCM) REQUIRED BY THE SNS
Modification timeline
-
August 22, 2024Mod P00004 · Change Order$47.75M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Phlow Corp. | Department Of Health And Human Services | July 2, 2026 | $696.67M |
| Sri International | Department Of Health And Human Services | July 2, 2026 | $0 |
| Pfizer Inc | Department Of Health And Human Services | June 29, 2026 | $1.12B |
| Kymanox Corp | Department Of Health And Human Services | June 25, 2026 | $0 |
| Mckesson Specialty Distribution Llc | Department Of Health And Human Services | June 24, 2026 | $203.93M |
| Mriglobal | Department Of Health And Human Services | June 24, 2026 | $514.9K |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50322F80029?
Contract 75A50322F80029 is a federal contract awarded to Sagent Pharmaceuticals, Inc by Department Of Health And Human Services on August 22, 2024 for $47.75 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 0 times since the base award.
Who won contract 75A50322F80029?
Sagent Pharmaceuticals, Inc won contract 75A50322F80029 from Department Of Health And Human Services.
How much is contract 75A50322F80029 worth?
Contract 75A50322F80029 has obligated $0 to date but carries a potential ceiling of $47.75 million if fully funded and all options are exercised.